Cleveland Clinic and Brooks Automation Reveal New Biobanking Facility
The Cleveland Clinic and Brooks Automation have said they are launching a 21,000 square foot biorepository in Cleveland’s Fairfax neighbourhood to improve researchers’ study of human tissue samples and advance personalised medicine.
The facility will increase Cleveland Clinic’s existing biobanking capacity and accelerate translational research through streamlined patient consent processes and centralised storage.
“This new biorepository will be a critical resource for our scientists. Biobanking is essential for the evolution of personalised medicine. The ability to properly manage biological specimens and to compare diseased tissues side-by-side with healthy tissues, is essential to understanding the biological basis of a disease,” commented the Cleveland Clinic Chair, Serpil Erzurum, MD.
“As a leading healthcare organisation, this provides an unparalleled opportunity to advance understanding of many different diseases, enabling us to make discoveries that are directly benefitting our patients.”
The two-story building will be located on the Cleveland Clinic’s campus and is expected to be completed in summer 2019. Brooks Life Sciences, a division of Brooks Automation, will manage the onsite operations to include storing and maintaining high-value collections of biological material.
They will begin with the launch of a sample inventory process that will annotate each sample within the storage facility before moving material to the new biorepository.
“With an international reputation as a leader in medical research, Cleveland Clinic understands the value sample management plays in medical research and is committed to improving patient outcomes,” said Brooks Life Sciences President, Dusty Tenney.
“We are extremely proud to be partnering with Cleveland Clinic to manage the operations of its new biobank and to offer our expertise in sample management.”